NCT07680244 · Carl Zeiss Meditec-Dublin CoCe
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
What this study is about
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
View original scientific description
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Able and willing to make the required study visits.
- Able and willing to give written informed consent and follow study instructions.
- Able and willing to complete ophthalmic imaging.
- Adults 18 years of age or older. The subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area): Group A 1\. Subjects with absence of macular abnormalities Group B
- Subjects with Disruption of the vitreoretinal interface (VRI)
- Subjects with Intraretinal hyporeflective space (IRHS)
- Subjects with Subretinal hyporeflective space (SRHS)
- Subjects with IS/OS (Ellipsoid Zone) disruption
- Subjects with Retinal Pigment Epithelium (RPE) elevation
- Subjects with Retinal Pigment Epithelium (RPE) atrophy
- Other abnormalities
Exclusion criteria
- Inability to undergo the required tests.
- Unable to give consent or follow study instructions.
- Inability to fixate that precludes obtaining acceptable macula scans in the study eye.
- Visudyne (verteporfin) injection within the last 48 hours in the study eye.
- Pilocarpine or Vuity use within the last 24 hours in the study eye.
- Dense media opacity precluding adequate visualization of the retina in the study eye.
- Vitreous floaters that preclude obtaining acceptable scans in the study eye.
Where
- Tucson, Arizona
- Mountain View, California
- San Francisco, California
- Fort Lauderdale, Florida
- Portland, Maine
- Kansas City, Missouri
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jul 2, 2026 · Source of record for eligibility and locations